Literature DB >> 34588195

Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database.

Charles Khouri1,2,3, Alex Hlavaty4, Matthieu Roustit2,3, Jean-Luc Cracowski4,3, Marie-Camille Chaumais5,6,7, Marc Humbert7,8,9, David Montani7,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34588195     DOI： 10.1183/13993003.01576-2021

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

1.  Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation.

Authors:  Daisetsu Aoyama; Shigefumi Fukui; Haruhiko Hirata; Keiko Ohta-Ogo; Hideo Matama; Emi Tateishi; Tatsuya Nishii; Yasuhide Asaumi; Mamoru Toyofuku; Tatsuyoshi Ikeue; Takeshi Ogo; Hatsue Ishibashi-Ueda; Satoshi Yasuda
Journal:  Pulm Circ       Date:  2022-02-21       Impact factor: 2.886

Review 2.  Differentiating pulmonary hypertension associated with protein kinase inhibitors.

Authors:  Joshua A Jacobs; Eiman Jahangir; John J Ryan
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.